欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Deferasirox Fe3+ chelate_554435-83-5_产品详情
554435-83-5
  • Deferasirox Fe3+ chelate

  • names:

    Deferasirox Fe3+ chelate

  • CAS号:

    554435-83-5

    MDL Number:
  • MF(分子式): C21H12FeN3O4 MW(分子量): 426.18
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Deferasirox Fe3+ chelate
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM004745-5mg 5mg >98.0% ¥ 2970.00 ¥ 2970.00 2-3天
- +
¥ 0.00
YZM004745-2mg 2mg >98.0% ¥ 1302.60 ¥ 1302.60 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名 Deferasirox Fe3+ chelate
CAS号 554435-83-5
Inchi
InchiKey
分子式 Formula C21H12FeN3O4
分子量 Molecular Weight 426.18
溶解度Solubility 生物体外In Vitro:DMSO溶解度50 mg/mL(117.32 mM;Need ultrasonic)
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years 4°C 2 years / In solvent溶液中: -80°C 6 months月 -20°C 1 month月
产品说明
IntroductionDeferasirox Fe3+ chelate is a rationallyesigned oral iron chelator; its main use is to reduce chronic iron overload in patients who are receiving longerm blood transfusions for conditions such as betahalassemia and other chronic anemias.
Application1
Application2
Application3
Deferasirox Fe3+ chelate is a rationally-designed oral iron chelator; its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Yang LP, Keam SJ, Keating GM. Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
【2】.Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010 Jul;9(4):633-41.
【3】.Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):123-34.
【4】.Donnelly JP, Lahav M. Deferasirox as adjunctive therapy for mucormycosis. J Antimicrob Chemother. 2012 Mar;67(3):519-20.
【5】.Lui GY, Obeidy P, Ford SJ et al. The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Mol Pharmacol. 2012 Oct 16. [Epub ahead of print]
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents